logo

Humanigen, Inc (HGEN)



Trade HGEN now with
  Date
  Headline
6/14/2021 6:34:29 AM Humanigen Begins Rolling Review Submission For Marketing Authorization By MHRA For Lenzilumab
4/19/2021 7:11:13 AM Humanigen Reports Positive Data With Lenzilumab In ZUMA-19 CAR-T Phase 1b Study In DLBCL
4/9/2021 7:03:01 AM Humanigen Announces Positive Results From Phase 1 Study Of Ifabotuzumab In Glioblastoma Multiforme
3/29/2021 7:07:49 AM Humanigen Announces Positive Topline Results From Phase 3 Clinical Trial Evaluating Lenzilumab
2/8/2021 7:10:10 AM Humanigen Elects Dale Chappell To Board
1/29/2021 7:21:15 AM Humanigen Completes Enrollment In Phase 3 Study Of Lenzilumab In Hospitalized Patients With COVID-19
1/27/2021 7:27:41 AM Ajinomoto Bio-Pharma Services And Humanigen Expand Manufacturing Agreement
1/25/2021 8:53:50 AM Emergent, Humanigen Enter Contract Development And Manufacturing Services Agreement For Lenzilumab
1/22/2021 7:07:10 AM Humanigen Announces Addition Of BARDA And Expansion Of CRADA With U.S. Government To Develop Lenzilumab For COVID-19
1/10/2021 8:32:35 AM Humanigen And EVERSANA Announce Partnership To Support Launch And Commercialization Of Lenzilumab For COVID-19
12/28/2020 7:06:42 AM Humanigen Gets U.S. Patent For Lenzilumab In Preventing Cytokine Storm And Neurotoxicity Related To CAR-T Cell Therapy
12/17/2020 7:30:46 AM Humanigen Completes Enrollment In Phase 1 Study Of Ifabotuzumab In Glioblastoma Multiforme
11/11/2020 7:23:50 AM Humanigen Q3 Loss/Shr $0.71 Vs Loss $0.11 Last Year